Clinical experience with latanoprost: A retrospective study of 153 patients

Acta Ophthalmologica Scandinavica

Volumn 77, Issue 3, 1999, Pages 336-339

  Martin, Lene ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glaucoma; Intraocular pressure; Latanoprost; Treatment

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST;

ADULT; AGED; ARTICLE; ASTHMA; CONJUNCTIVITIS; DRUG EFFICACY; ECZEMA; FEMALE; HEADACHE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 0032972193     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.1999.770318.x     Document Type: Article

References (21)

1. Alm A & Stjernchantz J, the Scandinavian Latanoprost Study Group (1995): Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102: 1743-1752.
2. Aim A, Widengård I, Kjellgren D, Söderström M, Friström B & Heijl A, Stjernschantz J (1995): Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 102: 1743-1752.
3. Bito LZ (1997): Prostaglandins: a new approach to glaucoma management with a new intriguing side effect. Surv Ophthalmol 41. Suppl 2: S1-14.
4. Camras CB, Alm A, Watson P & Stjernchantz J (1996): Latanoprost a prostaglandin analog for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 103: 1916-1924.
5. 2a on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res 6: 1035-1044.
6. Friström B & Nilsson SEG (1993): Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. Arch Ophthalmol 111: 662-665.
7. 2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49: 389-402.
8. Hyong PF, Rulo A, Greve E, Watson P & Alm A (1997): The additative intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol suppl 2: S93-98.
9. Lindén C & Alm A (1997): Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. Acta Ophthalmol Scand 75: 412-415.
10. Martin L & Wanger P (1998): Five-year follow up of treated patients with glaucoma using resolution perimetry. Journal of Glaucoma 7: 22-36.
11. Nagasubramanian S, Sheth GP, Hitchings RA & Stjernschantz J (1993): Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 100: 1305-1311.
12. 2a-1-isopropylester in the cynomolgus monkey. Exp Eye Res 48: 707-716.
13. Patelska B, Greenfield DS, Liebman JM, Wand M, Kushnick H & Ritch R (1997): Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 124: 279-286.
14. 2a analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 78: 899-902.
15. Rulo AH, Greve EL, Geijssen HC & Hoyng PFJ (1996): Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 103: 1276-1282.
16. 2a analogue, on aqueous humor dynamics in human eyes. Ophthalmology 100: 1297-1304.
17. 2a analogue: effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 76: 214-217.
18. Watson P & Stjernchantz J, the Latanoprost Study Group (1996): A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103:126-137
19. Watson PG (1998): Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology 105: 82-87.
20. Wistrand PJ, Stjernschantz J & Olsson K (1997): The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 41 Suppl 2: S129-138.
21. 2a analogue, after topical administration in normal and ocular hypertensive eyes. Arch Ophthalmol 111:1351-1358.